NO20003807L - <alfa>-ketoamidinhibitorer av 20S proteasome - Google Patents

<alfa>-ketoamidinhibitorer av 20S proteasome

Info

Publication number
NO20003807L
NO20003807L NO20003807A NO20003807A NO20003807L NO 20003807 L NO20003807 L NO 20003807L NO 20003807 A NO20003807 A NO 20003807A NO 20003807 A NO20003807 A NO 20003807A NO 20003807 L NO20003807 L NO 20003807L
Authority
NO
Norway
Prior art keywords
proteasome
alpha
ketoamide inhibitors
ketoamide
inhibitors
Prior art date
Application number
NO20003807A
Other languages
English (en)
Other versions
NO20003807D0 (no
NO327049B1 (no
Inventor
Lisa Wang
Robert T Lum
Steven R Schow
Alison Joly
Suresh Kerwar
Michael M Wick
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20003807D0 publication Critical patent/NO20003807D0/no
Publication of NO20003807L publication Critical patent/NO20003807L/no
Publication of NO327049B1 publication Critical patent/NO327049B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20003807A 1998-01-26 2000-07-25 alfa-ketoamid forbindelser samt farmasoytisk sammensetning innholdende slike NO327049B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/013,365 US6075150A (en) 1998-01-26 1998-01-26 α-ketoamide inhibitors of 20S proteasome
PCT/US1999/001097 WO1999037666A1 (en) 1998-01-26 1999-01-19 α-KETOAMIDE INHIBITORS OF 20S PROTEASOME

Publications (3)

Publication Number Publication Date
NO20003807D0 NO20003807D0 (no) 2000-07-25
NO20003807L true NO20003807L (no) 2000-09-25
NO327049B1 NO327049B1 (no) 2009-04-14

Family

ID=21759598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003807A NO327049B1 (no) 1998-01-26 2000-07-25 alfa-ketoamid forbindelser samt farmasoytisk sammensetning innholdende slike

Country Status (20)

Country Link
US (2) US6075150A (no)
EP (1) EP1058689A1 (no)
JP (1) JP3863370B2 (no)
KR (1) KR100417888B1 (no)
CN (1) CN1289340A (no)
AR (1) AR012781A1 (no)
AU (1) AU747835B2 (no)
BR (1) BR9907256A (no)
CA (1) CA2319150C (no)
GE (1) GEP20032869B (no)
HU (1) HUP0100901A3 (no)
IL (2) IL137475A0 (no)
NO (1) NO327049B1 (no)
NZ (1) NZ505892A (no)
PL (1) PL202504B1 (no)
RU (1) RU2192429C2 (no)
TW (1) TW593339B (no)
UA (1) UA71559C2 (no)
WO (1) WO1999037666A1 (no)
ZA (1) ZA99161B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
EP1395548A1 (en) 2001-02-26 2004-03-10 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
EP1465862A1 (en) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
KR20040099425A (ko) * 2002-04-11 2004-11-26 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4프로테아제의 억제제
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
EP2030981B1 (en) * 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20070027067A1 (en) * 2005-05-13 2007-02-01 Felicia Etzkorn Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー.フェー. 腫瘍の治療
JP5230416B2 (ja) 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ C型肝炎ウイルスの大員環状阻害剤
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
MY171061A (en) * 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
US8594771B2 (en) * 2005-12-28 2013-11-26 General Electric Company Devices and methods for self-administered ECG examinations
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
AU2012294493B2 (en) 2011-08-11 2017-02-23 Janssen Pharmaceutica Nv Predictors for cancer treatment
JP6238900B2 (ja) 2011-10-28 2017-11-29 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nae阻害物質に対する応答のバイオマーカー
CN104126017A (zh) 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP2904115B1 (en) 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
HK1212997A1 (zh) * 2012-10-11 2016-06-24 F. Hoffmann-La Roche Ag 酮酰胺免疫蛋白酶体抑制剂
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
JP6859559B2 (ja) * 2017-03-16 2021-04-14 二村 芳弘 抗アレルギー作用を呈するフェニルペプチド誘導体
JP7219473B2 (ja) * 2017-08-28 2023-02-08 静岡県公立大学法人 コリバクチンおよびコリバクチン産生菌の検出方法および検出プローブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
JPH04211648A (ja) * 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
US5430022A (en) * 1990-05-14 1995-07-04 Fujisawa Pharmaceutical Co., Ltd. Peptide compound and its preparation
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones

Also Published As

Publication number Publication date
CN1289340A (zh) 2001-03-28
CA2319150A1 (en) 1999-07-29
GEP20032869B (en) 2003-01-27
EP1058689A1 (en) 2000-12-13
UA71559C2 (en) 2004-12-15
AR012781A1 (es) 2000-11-08
IL137475A0 (en) 2001-07-24
TW593339B (en) 2004-06-21
WO1999037666A1 (en) 1999-07-29
US6075150A (en) 2000-06-13
PL343269A1 (en) 2001-08-13
HUP0100901A2 (hu) 2001-08-28
HUP0100901A3 (en) 2001-11-28
AU747835B2 (en) 2002-05-23
BR9907256A (pt) 2001-10-09
JP3863370B2 (ja) 2006-12-27
PL202504B1 (pl) 2009-06-30
NO20003807D0 (no) 2000-07-25
US6781000B1 (en) 2004-08-24
ZA99161B (en) 1999-07-28
AU2326799A (en) 1999-08-09
KR20010034381A (ko) 2001-04-25
IL137475A (en) 2006-10-05
RU2192429C2 (ru) 2002-11-10
KR100417888B1 (ko) 2004-02-11
JP2002501080A (ja) 2002-01-15
NO327049B1 (no) 2009-04-14
NZ505892A (en) 2002-10-25
CA2319150C (en) 2004-08-31

Similar Documents

Publication Publication Date Title
NO20003807L (no) &lt;alfa&gt;-ketoamidinhibitorer av 20S proteasome
DK1022334T3 (da) Hidtil ukendte amylaser
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
EP1110149A4 (en) Collaborative object architecture
DK1105422T3 (da) Hepatitis C-inhibitorpeptider
FI962800L (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
NO20030885L (no) Inhibitorer av &lt;alfa&gt;4 styrt celleadhesjon
EP1052692A4 (en) CONTAINER
DE69908387D1 (de) Pflanzenaktivierungsmittel
DE69922097D1 (de) Kessel
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE60142754D1 (de) Electrophoretische Kasette zur Detektion von Biopolymeren
DE59803815D1 (de) Klärschlammvererdung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
FR2777096B3 (fr) Horloge
NO20012276D0 (no) Identifisering av SENV-genotyper
NO982014D0 (no) FremgangsmÕte for beregning av varighet av oppkoblinger
NO20010280D0 (no) &lt;Alfa&gt;-aminosyrefenylesterderivater
FR2783036B1 (fr) Agencement de lampes indicatrices
ITUD980038A0 (it) Indicatore di livello
KR980003137U (ko) 퇴수를 재공급 사용토록 한 개량부동전
ID22787A (id) Nitro-benzamida berguna sebagai zat anti - arritimia
FI980930A0 (fi) Alus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees